Generex Initiates Dosing for Phase III Diabetes Trial
Posted on: Monday, 9 June 2008, 06:00 CDT
Generex Biotechnology has commenced dosing of patients in a Phase III clinical trial of the company's flagship product, Generex Oral-lyn, an oral insulin spray.
The six-month Phase III study will involve up to 750 patients with Type-1 diabetes mellitus in 36 centers located in the US, Canada, Russia and eastern Europe.
The objective of the study is to compare the efficacy of Generex Oral-lyn and the company's RapidMist diabetes management system with prandial injections of regular human insulin as measured by HbA1c.
Generex Oral-lyn, a liquid formulation of human regular insulin, is sprayed into the mouth with a simple device similar to inhalers used for the treatment of asthma.
Philip Raskin, managing director of the University of Texas Southwestern Medical Center at Dallas, said: "Diabetes mellitus is an overwhelming worldwide problem. Many people do not achieve their treatment goals because of failure to use insulin. As a principal investigator, I am pleased to announce that the international Phase III non-inferiority study of 750 patients has dosed its first patient."
Source: Datamonitor
Related Articles
- SDI Reports: Top 20% of Endocrinologists Write 95% of New-to-Brand Oral Diabetes Prescriptions
- Infinity Initiates Clinical Development of IPI-493, Its Oral Anti-Chaperone Agent, in Patients With Advanced Solid Tumors; Initiation of Phase 1 Expands Infinity's Leading Hsp90 Inhibitor Portfolio
- Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
- Oramed Granted Approval for Phase IIA Diabetic Study
- Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis
- Death Risk Halts Diabetes Study
- Delcath Resumes Enrollment in Phase III and Phase II Trials
- Inhaled Form of Insulin for Diabetics Studied
- The CARDS Investigators: Primary Prevention of Cardiovascular Disease With Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo- Controlled Trial
- Plasma Glucose Responses in Recreational Divers With Insulin- Requiring Diabetes
 |
 |
User Comments (0)
RSS Feeds